The benefits of tirzepatide, according to the science

Tirzepatide is the first medication of its kind: a single molecule that activates two incretin receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Older therapies such as semaglutide act on GLP-1 alone. Adding GIP appears to amplify insulin sensitivity, improve how the body stores and burns fat, and blunt appetite more completely, which is why the clinical results have been so striking.

What the trials actually showed

The landmark SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity or overweight without diabetes. After 72 weeks, participants lost an average of 15% of body weight on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, compared with 3.1% on placebo. More than half of those on the higher doses lost at least 20% of their starting weight — a result previously seen almost exclusively after bariatric surgery.

SURMOUNT-4 addressed the harder question of durability. Participants who continued tirzepatide after an initial lead-in period kept losing weight, reaching roughly 26% total reduction at 88 weeks, while those switched to placebo regained about half of what they had lost. The message is clear: obesity behaves like a chronic condition, and ongoing treatment matters.

For people living with type 2 diabetes, the SURPASS program showed HbA1c reductions of roughly 2.0 to 2.4 percentage points, with a majority of participants reaching an HbA1c below 5.7% — the non-diabetic range. In the head-to-head SURPASS-2 trial, tirzepatide outperformed semaglutide 1 mg on both blood sugar and weight.

Benefits beyond the scale

The evidence now extends well past body weight. SUMMIT, published in 2024, found that tirzepatide reduced the risk of worsening heart failure or cardiovascular death by 38% in patients with HFpEF and obesity, while improving symptom scores and six-minute walk distance. SURMOUNT-OSA reported that participants with moderate-to-severe obstructive sleep apnea saw apnea-hypopnea events fall by roughly 25 to 29 per hour — enough that many no longer met the criteria for moderate disease.

Trials have also documented improvements in blood pressure, triglycerides, LDL cholesterol, liver fat and markers of non-alcoholic steatohepatitis, and inflammatory markers such as C-reactive protein. Participants consistently report better physical function and quality of life, which is often what people notice first: stairs, hikes, and long bike rides that used to feel heavy simply do not anymore.

How it feels day to day

Most patients describe a quieting of what researchers call food noise — the constant background negotiation with hunger. Tirzepatide slows gastric emptying and acts on appetite centres in the hypothalamus, so meals end sooner and cravings lose urgency. That biological change is what makes nutrition and training habits finally stick.

Safety and what to expect

The most common side effects are gastrointestinal: nausea, diarrhoea, constipation, and reflux. They are usually mild to moderate, concentrate in the first weeks after each dose increase, and fade with time. This is exactly why dose titration should be physician-led rather than rushed. Tirzepatide is not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or MEN2, and it should be paired with adequate protein intake and resistance training to protect lean mass.

The Kove RX approach

Every tirzepatide plan at Kove RX is prescribed and monitored by a board-certified physician, with continued care through your patient portal for the length of your program. Your doctor sets the dose that fits your history — and if your dose needs to increase, your price does not.

This article is for educational purposes and is not medical advice. Talk with a licensed clinician about whether tirzepatide is right for you.